Elsevier

Lung Cancer

Volume 75, Issue 2, February 2012, Pages 156-160
Lung Cancer

Smoking history and lung carcinoma: KRAS mutation is an early hit in lung adenocarcinoma development

https://doi.org/10.1016/j.lungcan.2011.07.013Get rights and content

Abstract

Background

In a European multicenter prospective study patients with lung cancer were interviewed for smoking history and biological samples centrally collected. The aim of this study was to compare KRAS mutation analysis with smoking status at the time of diagnosis.

Methods

A nested case-study was performed on 233 non-small cell lung carcinomas. Cases were selected on the basis of progressive disease or disease-free post surgery based on specific criteria. KRAS mutation analysis was performed with the point-EXACCT method.

Results

KRAS mutations were found in 39 adenocarcinomas and 1 squamous cell carcinoma in the 233 NSCLC. The median quitting smoking time (QST) for patients with and without KRAS mutations was 9 years, interquartile range [IQR 16–38] and 3 years, IQR [13–50], respectively (p = 0.039). No difference was found for age at initiation of smoking, duration of smoking, average tobacco consumption, and smoking status at the time of diagnosis.

Conclusion

The QST was longer for patients with KRAS mutations, supporting the notion that the presence of a KRAS mutation is a dominant early effect, supporting its role as a driver oncogen.

Introduction

Smoking is the major etiologic factor in lung cancer and associated with the following major histological subtypes: small cell carcinoma, non small cell lung cancer, squamous cell carcinoma and adenocarcinoma.

In smokers with an adenocarcinoma of the lung KRAS mutations occur more frequently than in tumours from non-smokers [1], [2], [3], [4], [5]. It has been demonstrated in a number of studies that KRAS mutations occur early in the development of pulmonary adenocarcinomas [6] and are detectable in precursor lesions of atypical adenomatous hyperplasia [7].

Smoking is considered to be the dominant carcinogenesis initiating agent in the development of lung cancer, and KRAS mutations are most likely one of the first molecular events and have been demonstrated after more than 15 years of quitting smoking [8]. However, the unanswered question is whether the quitting smoking time (QST) in ex-smokers with pulmonary adenocarcinoma, is longer for those with KRAS mutation than those without this mutation. In a small study by Westra et al. the presence of KRAS mutations appeared to be independent of duration of abstinence from smoking [8]. The aim of this study was to compare KRAS mutation analysis with smoking status within a subset of the EUELC recruited population. In the EUELC multicenter study, patients with lung cancer were interviewed for a wide range of epidemiological and clinical parameters, including smoking history. In addition, biological samples were collected in a central EU Biobank based in Liverpool, UK [9]. From this population a cohort of patients with progressive disease and disease free post surgery was selected. The time since quitting smoking was longer for patients with KRAS mutation than for those without KRAS mutation, suggesting that KRAS mutation is an early event in lung carcinogenesis.

Section snippets

Materials and methods

Lung cancer cases were collected by 10 different centres in a EU framework 5 funded prospective study [9]. All patients were interviewed around the time of lung cancer diagnosis and asked to complete a detailed epidemiological/clinical questionnaire which also included smoking status. 913 patients were recruited into the EUELC and a nested case study was set up for patients with progressive disease (PD) and disease free (DF) status.

Progressive disease (PD) are patients with a history of a

Results

The clinical data are shown in Table 1. KRAS analyses showed mutations in 40 (17%) of the 233 cases. 39 of the 40 (97.5%) mutated cases were adenocarcinomas.

The type of mutations were TGT n = 26, GTT n = 9, AGT n = 1 and GAT n = 4, respectively. One of the patients had a double mutation GTT plus GCT. Note that most mutations were transversion mutations (88%). KRAS mutations were not associated with disease progression (p = 0.36).

The clinical variables related to the KRAS status are shown in Table 2. No

Discussion

This study demonstrates that the quitting smoking time (QST) in patients with lung cancer was longer for those with KRAS mutations than without KRAS mutations. From these results it may be argued that KRAS mutations are a very early event in carcinogenesis of pulmonary adenocarcinomas and this is in agreement with animal model studies suggesting that KRAS mutations occur early in lung tumour [16], [17], [18], [19], [20], [21].

The QST was not found to be normally distributed as may be seen from

Summary

Time to quit smoking before the development of lung cancer was longer for patients with KRAS mutations than those without, supporting the notion that the presence of a KRAS mutation is a early and dominant effect.

Conflict of interest

The authors have no financial disclosures on this subject.

The Research Project was supported by an EU Framework 5 grant (QLG1-CT-2002-01735).

The sponsor had no involvement in the study design, collection, analysis or interpretation of data; writing of the manuscript; or decision to submit the manuscript for publication.

Acknowledgements

The authors wish to thank all of the patients who agreed to participate in this European lung cancer research project.

References (37)

  • Z.H. Li et al.

    c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung

    Am J Pathol

    (1994)
  • C.A. Cooper et al.

    The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung

    J Pathol

    (1997)
  • W.H. Westra et al.

    K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung

    Cancer

    (1993)
  • J.K. Field et al.

    EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration

    Eur Respir J

    (2009)
  • V.A. Somers et al.

    A rapid, reliable method for detection of known point mutations: point-EXACCT

    Nucleic Acids Res

    (1994)
  • V.A. Somers et al.

    Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT

    J Clin Oncol

    (1998)
  • V.A. Somers et al.

    Validation of the Point-EXACCT method in non-small cell lung carcinomas

    Clin Chem

    (1998)
  • C.H. Klaassen et al.

    DNA microarray format for detection and subtyping of human papillomavirus

    J Clin Microbiol

    (2004)
  • Cited by (15)

    • Genetic mutation screen in early non-small-cell lung cancer (NSCLC) specimens

      2014, Clinical Lung Cancer
      Citation Excerpt :

      Reflex testing for mutations in common driver oncogenes has been suggested as a strategy to identify prognostic markers and potentially to direct adjuvant treatments.6-8 Indeed, the major oncogenes involved in lung cancer are probably mutated at an early stage of the disease.9-11 The evidence regarding the prognostic role of these mutations in early NSCLC is conflicting, with some studies showing no prognostic value,12-15 and others that indicate that significant information can be identified using this approach.6,7

    View all citing articles on Scopus
    1

    Former address: Department of Pathology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.

    2

    see Appendix table.

    View full text